ImageneBio Inc (IMA)
$4.24-0.24%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $48M
- Beta
- 0.74
- P/E (TTM)
- -0.81
- Short % float
- 0.44%
- Days to cover
- 1.9
- SI change
- -5.0%
- 1W
- -7.83%
- 1M
- -15.20%
- vs SPY 1W
- -7.69%
- vs SPY 1M
- -17.71%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 25
- GROWTH
- 47
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-23.4%
REV YoY-
ROE-39.0%
EPS YoY-
ROA-34.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.81
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.48
P/FCF-
EV/EBITDA0.85
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.35
ALTMAN Z-
CURR RATIO21.47
ND/EBITDA-
BETA0.74
Company news
FAQ
- What is LOPJLB’s current signal on IMA?
- LOPJLB’s latest quantitative signal on ImageneBio Inc (IMA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMA in?
- ImageneBio Inc (IMA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ImageneBio Inc (IMA) do?
- ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was forme…